Celladon Completes Enrollment of CUPID 2 Trial for Advanced Heart Failure NASDAQ SAN DIEGO, March 4, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced ... |
